vs
Side-by-side financial comparison of KEMPER Corp (KMPR) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $1.1B, roughly 1.3× KEMPER Corp). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs -0.7%, a 5.1% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs -4.7%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $166.2M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs -0.5%).
Kemper Corporation is an American insurance provider with corporate headquarters located in Chicago, Illinois. With nearly $13 billion in assets, the Kemper family of companies provides insurance to individuals, families, and businesses.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
KMPR vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.5B |
| Net Profit | $-8.0M | $66.5M |
| Gross Margin | — | 90.5% |
| Operating Margin | — | 12.4% |
| Net Margin | -0.7% | 4.4% |
| Revenue YoY | -4.7% | 32.8% |
| Net Profit YoY | -108.2% | 143.8% |
| EPS (diluted) | $-0.03 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $1.2B | $1.0B | ||
| Q2 24 | $1.1B | $929.2M | ||
| Q1 24 | $1.1B | $751.7M |
| Q4 25 | $-8.0M | $66.5M | ||
| Q3 25 | $-21.0M | $124.8M | ||
| Q2 25 | $72.6M | $94.3M | ||
| Q1 25 | $99.7M | $1.3M | ||
| Q4 24 | $97.4M | $-151.9M | ||
| Q3 24 | $73.7M | $-121.3M | ||
| Q2 24 | $75.4M | $-120.4M | ||
| Q1 24 | $71.3M | $-251.2M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 86.1% | ||
| Q2 25 | — | 87.5% | ||
| Q1 25 | — | 85.2% | ||
| Q4 24 | — | 85.8% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 85.1% | ||
| Q1 24 | — | 83.4% |
| Q4 25 | — | 12.4% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | -7.0% | ||
| Q3 24 | 11.2% | -12.0% | ||
| Q2 24 | 10.1% | -11.5% | ||
| Q1 24 | 7.6% | -34.8% |
| Q4 25 | -0.7% | 4.4% | ||
| Q3 25 | -1.7% | 8.8% | ||
| Q2 25 | 5.9% | 7.2% | ||
| Q1 25 | 8.4% | 0.1% | ||
| Q4 24 | 8.2% | -13.5% | ||
| Q3 24 | 6.3% | -12.1% | ||
| Q2 24 | 6.7% | -13.0% | ||
| Q1 24 | 6.2% | -33.4% |
| Q4 25 | $-0.03 | $0.05 | ||
| Q3 25 | $-0.34 | $0.08 | ||
| Q2 25 | $1.12 | $0.06 | ||
| Q1 25 | $1.54 | $0.00 | ||
| Q4 24 | $1.51 | $-0.10 | ||
| Q3 24 | $1.14 | $-0.09 | ||
| Q2 24 | $1.16 | $-0.09 | ||
| Q1 24 | $1.10 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $4.5B |
| Total DebtLower is stronger | $943.5M | $836.4M |
| Stockholders' EquityBook value | $2.7B | $4.4B |
| Total Assets | $12.5B | $8.2B |
| Debt / EquityLower = less leverage | 0.35× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.5B | ||
| Q3 25 | $371.2M | $4.0B | ||
| Q2 25 | $407.6M | $2.8B | ||
| Q1 25 | $545.3M | $2.5B | ||
| Q4 24 | $1.0B | $2.6B | ||
| Q3 24 | $696.9M | $2.7B | ||
| Q2 24 | $539.1M | $2.6B | ||
| Q1 24 | $520.7M | $2.8B |
| Q4 25 | $943.5M | $836.4M | ||
| Q3 25 | $943.1M | — | ||
| Q2 25 | $942.6M | — | ||
| Q1 25 | $942.1M | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $2.7B | $4.4B | ||
| Q3 25 | $2.7B | $4.1B | ||
| Q2 25 | $370.0M | $3.8B | ||
| Q1 25 | $366.0M | $3.5B | ||
| Q4 24 | $2.8B | $3.3B | ||
| Q3 24 | $2.8B | $3.4B | ||
| Q2 24 | $358.0M | $3.4B | ||
| Q1 24 | $2.6B | $3.4B |
| Q4 25 | $12.5B | $8.2B | ||
| Q3 25 | $12.4B | $7.6B | ||
| Q2 25 | $12.6B | $6.3B | ||
| Q1 25 | $12.5B | $5.8B | ||
| Q4 24 | $12.6B | $5.9B | ||
| Q3 24 | $12.6B | $5.8B | ||
| Q2 24 | $12.6B | $5.7B | ||
| Q1 24 | $12.6B | $5.7B |
| Q4 25 | 0.35× | 0.19× | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 2.55× | — | ||
| Q1 25 | 2.57× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 3.88× | — | ||
| Q1 24 | 0.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.0M | $417.3M |
| Free Cash FlowOCF − Capex | $166.2M | $379.8M |
| FCF MarginFCF / Revenue | 14.7% | 25.4% |
| Capex IntensityCapex / Revenue | 0.8% | 2.5% |
| Cash ConversionOCF / Net Profit | — | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $553.9M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.0M | $417.3M | ||
| Q3 25 | $139.9M | $402.6M | ||
| Q2 25 | $89.6M | $263.6M | ||
| Q1 25 | $180.0M | $44.1M | ||
| Q4 24 | $175.1M | $75.2M | ||
| Q3 24 | $141.9M | $188.4M | ||
| Q2 24 | $22.9M | $-95.6M | ||
| Q1 24 | $43.0M | $-308.6M |
| Q4 25 | $166.2M | $379.8M | ||
| Q3 25 | $133.4M | $354.5M | ||
| Q2 25 | $82.0M | $219.8M | ||
| Q1 25 | $172.3M | $-12.3M | ||
| Q4 24 | $165.4M | $-17.3M | ||
| Q3 24 | $131.4M | $54.7M | ||
| Q2 24 | $5.2M | $-205.5M | ||
| Q1 24 | $27.7M | $-465.1M |
| Q4 25 | 14.7% | 25.4% | ||
| Q3 25 | 10.8% | 25.1% | ||
| Q2 25 | 6.7% | 16.7% | ||
| Q1 25 | 14.4% | -1.1% | ||
| Q4 24 | 13.9% | -1.5% | ||
| Q3 24 | 11.1% | 5.5% | ||
| Q2 24 | 0.5% | -22.1% | ||
| Q1 24 | 2.4% | -61.9% |
| Q4 25 | 0.8% | 2.5% | ||
| Q3 25 | 0.5% | 3.4% | ||
| Q2 25 | 0.6% | 3.3% | ||
| Q1 25 | 0.6% | 5.0% | ||
| Q4 24 | 0.8% | 8.2% | ||
| Q3 24 | 0.9% | 13.3% | ||
| Q2 24 | 1.6% | 11.8% | ||
| Q1 24 | 1.3% | 20.8% |
| Q4 25 | — | 6.28× | ||
| Q3 25 | — | 3.22× | ||
| Q2 25 | 1.23× | 2.79× | ||
| Q1 25 | 1.81× | 34.71× | ||
| Q4 24 | 1.80× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.30× | — | ||
| Q1 24 | 0.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KMPR
| Specialty Property Casualty Insurance Segment | $995.1M | 88% |
| Life Insurance Segment1 | $140.7M | 12% |
ONC
Segment breakdown not available.
